Clinical Trials Logo

Clinical Trial Summary

The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.


Clinical Trial Description

Specific Aim 1: To compare the surgical site infection (SSI) rates of the current severe open fracture antibiotic strategy to a revised SEXTANT treatment strategy designed to address the modern wound bioburden at the time of wound closure or coverage. Specific Aim 2: To compare the terminal bioburden of the wounds at the time of definitive closure or coverage as sampled by standard tissue microbiology. Specific Aim 3: To compare rates of antibiotic-related serious adverse events (SAEs) of the two treatment groups. Exploratory Aim 4: To pilot the use of available and emerging rapid PCR platforms for wound pathogen identification in a sub-cohort of patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04678154
Study type Interventional
Source Major Extremity Trauma Research Consortium
Contact Suna Chung, MPH
Phone 4105023357
Email schung60@jhu.edu
Status Recruiting
Phase Phase 3
Start date May 7, 2021
Completion date March 30, 2025

See also
  Status Clinical Trial Phase
Completed NCT02227446 - Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO) Phase 3
Recruiting NCT04597008 - Topical Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: TOBRA Phase 3
Completed NCT01798810 - Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery N/A